Predictors of cinacalcet discontinuation and reinitiation in hemodialysis patients: results from 7 European countries

BACKGROUND: The putative benefits of cinacalcet therapy for management of secondary hyperparathyroidism (SHPT) are thought to be most manifested when patients are taking it consistently and as prescribed. Real-world descriptions of cinacalcet prescription discontinuation and reinitiation in European...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :BMC Nephrol
Главные авторы: Fuller, Douglas S., Hallett, David, Dluzniewski, Paul J., Fouqueray, Bruno, Jadoul, Michel, Morgenstern, Hal, Port, Friedrich K., Tentori, Francesca, Pisoni, Ronald L.
Формат: Artigo
Язык:Inglês
Опубликовано: BioMed Central 2019
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6518810/
https://ncbi.nlm.nih.gov/pubmed/31088377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-019-1355-5
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы